Atomoxetine in the Treatment of Binge Eating Disorder

Atomoxetine in the Treatment of Binge Eating Disorder: A Single-Center, Double-Blind, Placebo-Controlled, Flexible Dose Study in Outpatients

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00327834

Enrollment

Unknown

Registered

2006-05-19

Start date

2006-05-31

Completion date

2007-03-31

Last updated

2011-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Binge-eating Disorder

Brief summary

The specific aim of this study is to assess the efficacy and safety of atomoxetine compared with placebo in outpatients with binge eating disorder.

Interventions

DRUGatomoxetine

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* Subjects will meet the DSM-IV criteria for a diagnosis of binge-eating disorder for at least the last 6 months * In addition, subjects will report at least 3 binge eating episodes per week for the last 6 months prior to randomization

Exclusion criteria

* Have concurrent symptoms of bulimia nervosa or anorexia nervosa * Women who are pregnant, lactating, or of child bearing potential who are not using adequate contraceptive measures * Patients who are displaying clinically significant suicidality or homicidality

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 7, 2026